News and Announcements
Warburton Global Fund register +2.9% profit despite a ‘lukewarm’ September
- Published November 01, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Warburton Global Fund records a gain of +11.4% over the quarter.
- The fund has been in operation for 10 quarters and this is the 9th positive quarter.
- Series 1 of the Warburton Global Fund returned +2.9% in September.
Warburton Investment Management are pleased to announce that their Warburton Global Fund returned +2.9% despite a ‘lukewarm’ September.
Sovereign bond prices fell across the board and market equities registered moderate gains in aggregate, while the Warburton Global Fund registered a ‘decent’ profit for the month.
Series 1 units of the Warburton Global Fund returned +2.9% in September 2018. The value of $1 invested since inception is $2.12.
The fund recorded moderate gains in commodities (+2.5%) and equities (+1.0%), a small profit in fixed income (+0.1%) and a modest loss in our currency book (-0.6%).
The fund recorded a gain of +11.4% over the quarter.
About Warburton Investment Management
Warburton Investment Management manages client capital via the Warburton Global Fund, a global macro hedge fund that deals in international investments. The fund invests in public equity, fixed income, currency and commodity markets worldwide.
Founded in 2015, Warburton Investment Management is one of the best performing firms in the hedge fund industry, with a mandate to target annualised returns of over 30%.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
